Heat shock protein 25-enriched plasma transfusion preconditions the heart against doxorubicin-induced dilated cardiomyopathy in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 341, Issue 3, 2012, Pages 829-839

  Krishnamurthy, Karthikeyan ^a   Kanagasabai, Ragu ^a   Druhan, Lawrence J ^b   Ilangovan, Govindasamy ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; HEAT SHOCK PROTEIN 25; HEAT SHOCK PROTEIN 27; HEAT SHOCK TRANSCRIPTION FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RECOMBINANT PROTEIN; TOLL LIKE RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL ISOLATION; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; HEART FUNCTION; HEART MUSCLE CELL; HEART PROTECTION; LIFESPAN; MOUSE; NONHUMAN; PLASMA TRANSFUSION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; TREATMENT RESPONSE; WILD TYPE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BLOOD TRANSFUSION; CARDIOMYOPATHY, DILATED; CYTOKINES; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; DOXORUBICIN; ECHOCARDIOGRAPHY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HEAT-SHOCK PROTEINS; IMMUNOBLOTTING; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MICE; MICE, INBRED BALB C; MYOCYTES, CARDIAC; NEOPLASM PROTEINS; NF-KAPPA B; TIME FACTORS; TOLL-LIKE RECEPTORS; TRANSCRIPTION FACTORS;

EID: 84861545875     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.192245     Document Type: Article

References (45)

1. Baler R, Dahl G, and Voellmy R (1993) Activation of human heat shock genes is accompanied by oligomerization, modification, and rapid translocation of heat shock transcription factor HSF1. Mol Cell Biol 13:2486-2496. (Pubitemid 23097727)
2. Boyd JH, Mathur S, Wang Y, Bateman RM, and Walley KR (2006) Toll-like receptor stimulation in cardiomyocytes decreases contractility and initiates an NF-κB dependent inflammatory response. Cardiovasc Res 72:384-393. (Pubitemid 44665856)
3. DeMeester SL, Buchman TG, and Cobb JP (2001) The heat shock paradox: does NF-κB determine cell fate? FASEB J 15:270-274. (Pubitemid 32061676)
4. Dhodapkar MV, Dhodapkar KM, and Li Z (2008) Role of chaperones and FcγR in immunogenic death. Curr Opin Immunol 20:512-517.
5. Dohke T, Wada A, Isono T, Fujii M, Yamamoto T, Tsutamoto T, and Horie M (2006) Proteomic analysis reveals significant alternations of cardiac small heat shock protein expression in congestive heart failure. J Card Fail 12:77-84. (Pubitemid 43267756)
6. Fan GC, Zhou X, Wang X, Song G, Qian J, Nicolaou P, Chen G, Ren X, and Kranias EG (2008) Heat shock protein 20 interacting with phosphorylated Akt reduces doxorubicin-triggered oxidative stress and cardiotoxicity. Circ Res 103:1270-1279.
7. Fisher PW, Salloum F, Das A, Hyder H, and Kukreja RC (2005) Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 111:1601-1610. (Pubitemid 40525159)
8. Habich C, Baumgart K, Kolb H, and Burkart V (2002) The receptor for heat shock protein 60 on macrophages is saturable, specific, and distinct from receptors for other heat shock proteins. J Immunol 168:569-576. (Pubitemid 34049555)
9. Herbst RS (2005) Role of novel targeted therapies in the clinic. Br J Cancer 92 (Suppl 1):S21-S27.
10. Huang C, Zhang X, Ramil JM, Rikka S, Kim L, Lee Y, Gude NA, Thistlethwaite PA, Sussman MA, Gottlieb RA, et al. (2010) Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice. Circulation 121:675-683.
11. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed, Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
12. Kardys I, Rifai N, Meilhac O, Michel JB, Martin-Ventura JL, Buring JE, Libby P, and Ridker PM (2008) Plasma concentration of heat shock protein 27 and risk of cardiovascular disease: a prospective, nested case-control study. Clin Chem 54:139-146. (Pubitemid 351182607)
13. Kim SC, Stice JP, Chen L, Jung JS, Gupta S, Wang Y, Baumgarten G, Trial J, and Knowlton AA (2009) Extracellular heat shock protein 60, cardiac myocytes, and apoptosis. Circ Res 105:1186-1195.
14. Kobayashi S, Volden P, Timm D, Mao K, Xu X, and Liang Q (2010) Transcription factor GATA4 inhibits doxorubicin-induced autophagy and cardiomyocyte death. J Biol Chem 285:793-804.
15. Kobba S, Kim SC, Chen L, Kim E, Tran AL, Knuefermann P, and Knowlton AA (2011) The heat shock paradox and cardiac myocytes: role of heat shock factor. Shock 35:478-484.
16. Krysko DV, Kaczmarek A, Krysko O, Heyndrickx L, Woznicki J, Bogaert P, Cauwels A, Takahashi N, Magez S, Bachert C, et al. (2011) TLR-2 and TLR-9 are sensors of apoptosis in a mouse model of doxorubicin-induced acute inflammation. Cell Death Differ 18:1316-1325.
17. Leslie SJ, Johnston N, Strachan FE, Bagnall A, Gray GA, Newby DE, Denvir MA, and Webb DJ (2004) Endothelin-1[1-31] is not elevated in men with chronic heart failure. J Cardiovasc Pharmacol 44:S96-S99. (Pubitemid 40039652)
18. Lewthwaite J, Owen N, Coates A, Henderson B, and Steptoe A (2002) Circulating human heat shock protein 60 in the plasma of British civil servants: relationship to physiological and psychosocial stress. Circulation 106:196-201. (Pubitemid 34761299)
19. Liu L, Zhang X, Qian B, Min X, Gao X, Li C, Cheng Y, and Huang J (2007) Over-expression of heat shock protein 27 attenuates doxorubicin-induced cardiac dysfunction in mice. Eur J Heart Fail 9:762-769. (Pubitemid 47214666)
20. Maslov MY, Chacko VP, Hirsch GA, Akki A, Leppo MK, Steenbergen C, and Weiss RG (2010) Reduced in vivo high-energy phosphates precede Adriamycin-induced cardiac dysfunction. Am J Physiol Heart Circ Physiol 299:H332-H337.
21. Minotti G, Menna P, Salvatorelli E, Cairo G, and Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185-229. (Pubitemid 38720829)
22. Mukhopadhyay P, Bátkai S, Rajesh M, Czifra N, Harvey-White J, Haskó G, Zsengeller Z, Gerard NP, Liaudet L, Kunos G, et al. (2007) Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol 50:528-536. (Pubitemid 47126779)
23. Multhoff G (2006) Heat shock proteins in immunity. Handb Exp Pharmacol 172:279-304.
24. Nozaki N, Shishido T, Takeishi Y, and Kubota I (2004) Modulation of doxorubicin-induced cardiac dysfunction in Toll-like receptor-2-knockout mice. Circulation 110:2869-2874. (Pubitemid 39473611)
25. Panasenko OO, Seit Nebi A, Bukach OV, Marston SB, and Gusev NB (2002) Structure and properties of avian small heat shock protein with molecular weight 25 kDa. Biochim Biophys Acta 1601:64-74. (Pubitemid 38234532)
26. Peng X, Chen B, Lim CC, and Sawyer DB (2005) The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine. Mol Interv 5:163-171. (Pubitemid 41018273)
27. Petersen CA, Krumholz KA, and Burleigh BA (2005) Toll-like receptor 2 regulates interleukin-1β-dependent cardiomyocyte hypertrophy triggered by Trypanosoma cruzi. Infect Immun 73:6974-6980. (Pubitemid 41368866)
28. Riad A, Bien S, Gratz M, Escher F, Westermann D, Heimesaat MM, Bereswill S, Krieg T, Felix SB, Schultheiss HP, et al. (2008) Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice. Eur J Heart Fail 10:233-243.
29. Roelofs MF, Boelens WC, Joosten LA, Abdollahi-Roodsaz S, Geurts J, Wunderink LU, Schreurs BW, van den Berg WB, and Radstake TR (2006) Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis. J Immunol 176:7021-7027. (Pubitemid 43787883)
30. Sakamoto M, Minamino T, Toko H, Kayama Y, Zou Y, Sano M, Takaki E, Aoyagi T, Tojo K, Tajima N, et al. (2006) Upregulation of heat shock transcription factor 1 plays a critical role in adaptive cardiac hypertrophy. Circ Res 99:1411-1418. (Pubitemid 44949677)
31. Sarge KD, Murphy SP, and Morimoto RI (1993) Activation of heat shock gene transcription by heat shock factor 1 involves oligomerization, acquisition of DNA-binding activity, and nuclear localization and can occur in the absence of stress. Mol Cell Biol 13:1392-1407. (Pubitemid 23068075)
32. Schmidt H, Saworski J, Werdan K, and Müller-Werdan U (2007) Decreased beating rate variability of spontaneously contracting cardiomyocytes after co-incubation with endotoxin. J Endotoxin Res 13:339-342.
33. Schmitt E, Gehrmann M, Brunet M, Multhoff G, and Garrido C (2007) Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J Leukoc Biol 81:15-27. (Pubitemid 46021247)
34. Shen F, Chu S, Bence AK, Bailey B, Xue X, Erickson PA, Montrose MH, Beck WT, and Erickson LC (2008) Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J Pharmacol Exp Ther 324:95-102. (Pubitemid 350294163)
35. Stacchiotti A, Bonomini F, Lavazza A, Rodella LF, and Rezzani R (2009) Adverse effects of cyclosporine A on HSP25, αB-crystallin and myofibrillar cytoskeleton in rat heart. Toxicology 262:192-198.
36. Turakhia S, Venkatakrishnan CD, Dunsmore K, Wong H, Kuppusamy P, Zweier JL, and Ilangovan G (2007) Doxorubicin-induced cardiotoxicity: direct correlation of cardiac fibroblast and H9c2 cell survival and aconitase activity with heat shock protein 27. Am J Physiol Heart Circ Physiol 293:H3111-H3121. (Pubitemid 350106537)
37. van de Klundert FA, Smulders RH, Gijsen ML, Lindner RA, Jaenicke R, Carver JA, and de Jong WW (1998) The mammalian small heat-shock protein Hsp20 forms dimers and is a poor chaperone. Eur J Biochem 258:1014-1021. (Pubitemid 29013540)
38. Vedam K, Nishijima Y, Druhan LJ, Khan M, Moldovan NI, Zweier JL, and Ilangovan G (2010) Role of heat shock factor-1 activation in the doxorubicin-induced heart failure in mice. Am J Physiol Heart Circ Physiol 298:H1832-H1841.
39. Vivanco F, Martín-Ventura JL, Duran MC, Barderas MG, Blanco-Colio L, Dardé VM, Mas S, Meilhac O, Michel JB, Tuñón J, et al. (2005) Quest for novel cardiovascular biomarkers by proteomic analysis. J Proteome Res 4:1181-1191. (Pubitemid 41208676)
40. Voellmy R (2005) Dominant-positive and dominant-negative heat shock factors. Methods 35:199-207.
41. Xiao X, Zuo X, Davis AA, McMillan DR, Curry BB, Richardson JA, and Benjamin IJ (1999) HSF1 is required for extra-embryonic development, postnatal growth and protection during inflammatory responses in mice. EMBO J 18:5943-5952. (Pubitemid 29515671)
42. Yan LJ, Christians ES, Liu L, Xiao X, Sohal RS, and Benjamin IJ (2002) Mouse heat shock transcription factor 1 deficiency alters cardiac redox homeostasis and increases mitochondrial oxidative damage. EMBO J 21:5164-5172.
43. Yokota S and Fujii N (2010) Immunomodulatory activity of extracellular heat shock proteins and their autoantibodies. Microbiol Immunol 54:299-307.
44. Yoshida M, Shiojima I, Ikeda H, and Komuro I (2009) Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATM-p53-apoptosis pathway and attenuated by pitavastatin through the inhibition of Rac1 activity. J Mol Cell Cardiol 47:698-705.
45. Zhu W, Soonpaa MH, Chen H, Shen W, Payne RM, Liechty EA, Caldwell RL, Shou W, and Field LJ (2009) Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation 119:99-106.